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Introduction
Focal nodular hyperplasia (FNH) is the second most 
common benign hepatic tumor after hemangioma (1). Con-
sidered to be a local hyperplastic response to a congenital 
vascular anomaly (2), FNH is most commonly found in 
women in their 3rd and 4th decades of  life (1). These le-
sions are typically found incidentally at autopsy, lapa-
rotomy, or radiologic investigation performed for another 
indication (3). FNH is composed of  normal hepatocytes 
that are abnormally arranged within a fibrous meshwork, 
usually with a prominent central fibrous scar or scars (1). 
The typical appearance of  FNH on imaging is a solid 
mass, less than 5 cm in size, with a central scar. FNH is well 
vascularized by thick-walled arteries; therefore, hemor-
rhage, necrosis, calcification, and infarction are rare. FNH 
appears as an iso-attenuating or slightly hypo-attenuating 
lesion on noncontrast-enhanced CT. Following intravenous 
contrast material administration, the mass enhances avidly 
in the late arterial phase and is isodense to surrounding 
normal hepatic parenchyma in the portal venous and equi-
librium phases. In approximately one-third of  cases, the 
central scar may appear hypo-attenuating on unenhanced 
CT, but visualization may be difficult. Overall, due to the 
variable vascularity and tissue composition of  the central 
scar, its appearance in various phases of  contrast and 
among different lesions is not predictable (1). 
Typically, FNH is iso- or slightly hypo-intense relative to 
normal hepatic parenchyma on unenhanced, T1-weighted 
MRI, with a hypointense central scar. On T2-weighted 
images, FNH tends to be iso- to subtly hyperintense, and 
the central scar is typically hyperintense. With intravenous 
administration of  gadolinium contrast material, there is 
avid, homogeneous enhancement of  the mass in the late 
arterial phase, with the exception of  the central scar. Dur-
ing the portal venous and equilibrium phases, the mass 
appears isointense, with the central scar enhancing in the 
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delayed phases (1). Hepatocyte-specific contrast agents may 
be used to differentiate FNH from other hypervascular he-
patic masses. These agents perform similarly to traditional 
extracellular gadolinium contrast on dynamic postcontrast 
imaging. Hepatocyte-specific contrast agents are variably 
taken up by hepatocytes and excreted into the biliary tree. 
More recently developed hepatocyte-specific agents, such as  
gadoxetate disodium, demonstrate up to 50% biliary excre-
tion, assuming normal hepatocyte function and the absence 
of  biliary obstruction. These agents allow imaging in the 
“hepatocyte phase,” approximately 20 minutes after con-
trast administration, and can help differentiate masses that 
are composed of  normal hepatocytes from those that are 
not. Lesions of  hepatocellular origin, including FNH and 
well-differentiated hepatocellular carcinoma, take up and 
retain hepatocyte-specific agents. Nonhepatocellular tu-
mors, such as metastases and cavernous hemangiomas, are 
hypointense relative to enhancing surrounding normal pa-
renchyma in the hepatocyte phase. FNH is composed of  
normal, densely packed hepatocytes and blind-ending duc-
tules with delayed biliary excretion; it therefore tends to 
retain contrast, with the lesion appearing isointense or 
hyperintense in the hepatocyte phase, with “popcorn-like” 
enhancement (4). Of  note, the central scar does not en-
hance in the hepatocyte phase (5). 
FNH has no malignant potential, and surgical excision is 
not indicated unless the patient is symptomatic (1). Since 
the 1970s, there has been controversy over the effect of  oral 
contraceptive pills (OCP) on the natural history of  FNH. 
Histologically, FNH in patients who use contraceptives 
tends to have greater vascular alterations, fibrosis, peliosis, 
and size (6). Spontaneous regression of  FNH is not un-
common, but cases of  near-complete regression or com-
plete involution are rare.
These two cases of  FNH underwent near-complete re-
gression. Between the initial diagnosis and subsequent re-
gression, both patients discontinued exogenous estrogen 
therapy.
Case report
Case 1: A 27-year-old female with a history of  oral con-
traceptive use presented with right-upper-quadrant ab-
dominal pain, nausea, and vomiting. 
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Figure 1. FNH in a 27-year old female with a history of oral 
contraceptive pill use. (A) Precontrast T1WI shows an isoin-
tense mass with a hypointense central scar (arrowhead) in 
segment 5 of the liver. (B) Following intravenous admini-
stration of gadobenate dimeglumine, a late arterial phase 
T1WI shows an avidly enhancing lobular mass (arrow) with 
a nonenhancing central scar (arrowhead). Note the hypo-
vascular fibrous septa radiating from the scar. (C) Five-
minute-delayed T1WI shows that the mass is isointense, 
with the liver parenchyma and the central scar enhancing. 
(D) A T2WI view with fat saturation shows the isointense 
mass and hyperintense central scar (arrowhead).
A transabdominal ultrasound examination demonstrated 
cholelithiasis and a 2.7-cm, hyperechoic, solid mass in the 
right lobe of  the liver. 
Dynamic contrast-enhanced magnetic resonance imag-
ing (MRI) to further evaluate the hepatic mass confirmed 
the presence of  a hypervascular mass with a central scar in 
hepatic segment 5, measuring 2.9 x 3.6 cm. The mass was 
hypo-intense on T1-weighted imaging, iso-intense to mildly 
hyperintense on T2-weighted imaging, and iso-intense on 
delayed postcontrast sequences. The central scar was 
hyperintense on T2-weighted imaging and demonstrated 
delayed enhancement (Fig. 1). 
Forty-eight months later, at which time OCP use was no 
longer documented in the patient’s chart, she underwent 
MRI of  the abdomen with and without contrast. On this 
followup study, the FNH lesion in the inferior right lobe of  
the liver had significantly regressed, measuring 0.6 x 0.8 cm 
in its largest dimensions (Fig. 2).
Case 2: A 46-year-old female with a four-year history of  
estrogen therapy (following salpingo-oopherectomy) and 
Cowden syndrome presented with right-lower-quadrant 
pain and underwent contrast-enhanced CT. A 6 x 5-cm 
enhancing mass with a central scar was observed in seg-
ment 2 of  the liver. 
Further evaluation with contrast-enhanced liver MRI 
confirmed a hypervascular mass with a central scar in seg-
ment 2, measuring 6.5 x 4.4 cm. In the late arterial phase, 
the mass enhanced avidly and homogeneously, with the 
exception of  the central scar. The mass was iso-intense on 
T1 and T2-weighted images, as well as on delayed postcon-
trast sequences. The central scar enhanced on delayed 
postcontrast images; however, it did not exhibit typical T2 
hyperintensity. Hemangiomas and cysts were also observed 
in the liver (Fig. 3).
Shortly after the initial diagnosis of  FNH was made, the 
patient discontinued estrogen replacement therapy. 
Ninety months after the initial diagnosis of  FNH, 
contrast-enhanced CT was performed to re-examine the 
patient’s liver lesions and evaluate a colonic lipoma. The 
previously observed FNH within the left lobe of  the liver 
had regressed to 2.1 x 1.9 cm (Fig. 4).
Discussion
FNH is the second most common tumor arising from the 
hepatic parenchyma. Because FNH typically occurs in 
women of  reproductive age, and a large proportion (50-
75%) of  patients with FNH are OCP users, many have 
speculated that hormones play a role in the pathogenesis of 
these tumors (1). Endogenous and exogenous estrogens 
play a clear role in the pathogenesis of  hepatic adenoma 
(7); their relationship with liver hemangioma and focal 
nodular hyperplasia has been the subject of  controversy 
(8-16). 
Since the 1970s, many cases of  FNH have been reported 
in patients taking both high- and low-dose OCPs. Some 
authors have suggested that OCPs are not the patho-
physiologic cause of  FNH (as in hepatic adenoma) (1); 
however, the correlation between regression of  FNH le-
sions and the discontinuation of  OCPs in several cases 
have suggested that exogenous estrogens may act as trophic 
agents (8, 16-21). Some groups have argued that FNH may 
regress spontaneously, regardless of  patients’ OCP use or 
endogenous hormonal status (10, 13, 14, 22-24). Others 
have posited that there is a direct association between OCP 
use and FNH (15), and that withdrawal of  OCPs may lead 
to its regression (12, 17-20). Several groups have reported 
data on the natural history of  FNH, the highlights of  
which are summarized in Table 1. 
To further investigate the posited association between 
OCP use and FNH from previous case-only and clinical 
observation studies, Scalori et al. (15) conducted a case-
control study of  23 patients with FNH and 94 matched 
control subjects. They concluded that, while endogenous 
hormonal factors are not associated with FNH, OCP use 
for ≥3 years is associated with it (OR = 4.5, 95% CI = 
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Figure 2. Near-complete regression of FNH in a 31-year-old female with a history of oral contraceptive use; images taken 48 
months after Fig. 1. (A) Precontrast T1WI shows that the segment 5 mass has significantly decreased in size (arrow). (B) Fol-
lowing intravenous administration of gadobenate dimeglumine, a late-arterial-phase T1WI shows no significant enhancement 
in the expected location of the mass. (C) Three-minute-delayed postcontrast T1WI shows a small focus of enhancement (ar-
row), residuum of the previously seen FNH. 
1.2-16.9). A trend in risk was noted with increased duration 
of  OCP use (χ2 = 5.19, p =0.023). Lastly, patient age <20 
at first use of  OCPs was also associated with FNH (OR = 
5.71, 95% CI = 1.20-27.14). In a subanalysis to identify 
characteristics that predict involution of  FNH, Kuo et al. 
reported that, though there were no differences between 
FNH lesions that decreased in size and those that did not, 
complete radiologic involution of  FNH lesions was associ-
ated with patients of  older age, and nodule diameter of  <2 
cm (p-values < 0.05). Multiple logistic regression analysis 
showed that both older age (OR =1.26, 95% CI = 1.02–
1.56) and longer followup time (OR 1.1, 95% CI 1.01–
1.21) were independent factors associated with complete 
involution of  FNH lesions (OR 1.1, 95% CI 1.01–1.21). 
Data from the case series presented by Leconte et al. (12) 
show that discontinuation of  OCPs at the time of  diagnosis 
of  FNH was associated with a trend toward decrease in 
lesion size.
Effect sizes in the aforementioned studies were modest. 
Because FNH is a rare entity, it has been difficult to study 
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Figure 4. A 53-year-old female with Cowdenʼs syndrome 
whose FNH lesion (arrow) has regressed. An enhanced CT 
image taken 90 months after Figure 3 shows marked invo-
lution of the mass in segment 2 of the liver. The mass 
measures 2.1 x 1.9 cm.
Figure 3. FNH in a 46-year-old female with Cowden syn-
drome and a history of hormone replacement therapy. (A) 
Precontrast T1WI shows a 6.5-x-4.4cm mass that is isoin-
tense to the liver parenchyma in segment 2 of the liver (ar-
row). (B) Following intravenous administration of gadodia-
mide, the mass avidly enhances in the late arterial phase 
T1WI. The fibrous central scar is nonenhancing (arrow-
head). (C) On a five-minute-delayed T1WI, the central scar 
enhances. Note that the left hepatic vein is displaced by the 
mass, mimicking rim enhancement. (D) On T2WI, the cen-
tral scar within this FNH lesion lacks typical hyperintensity.
its natural history in large groups of  patients. Moreover, 
existent studies of  the natural history of  FNH are difficult 
to compare given heterogeneity in imaging modalities used, 
parameters for defining change in size of  FNH lesion, 
length of  followup, diagnostic criteria, and other factors. 
Ample data about the frequency of  regression and invo-
lution of  FNH have been presented. While it is not unusual 
for FNH lesions to decrease in size, to our knowledge, only 
9 cases of  complete radiologic involution have been re-
ported (10, 13, 14, 19, 23). Among the lesions that com-
pletely involuted, no pattern can be discerned with regard 
to OCP use status. Six FNH lesions disappeared in patients 
with no significant history of  OCP use (23), two disap-
peared in spite of  ongoing OCP use (10, 13, 14), and one 
disappeared 5 years after the discontinuation of  OCPs (19). 
We present two cases of  near-complete regression of  
FNH; one patient’s FNH lesion decreased in size over the 
course of  a 4-year period, and the other over the course of  
a 7-year period. Both patients had a history of  exogenous 
estrogen use prior to the initial diagnosis of  FNH, and both 
discontinued estrogen therapy between their initial presen-
tation and near-complete involution of  their FNH lesions. 
The long duration of  followup in our cases was similar to 
that in the series presented by Kuo et al. (23), and may have 
improved our ability to detect regression of  our patients’ 
FNH lesions. There is not sufficient data to conclude that 
the natural history of  our patients’ lesions can be attributed 
to their cessation of  exogenous estrogen use. Nor is there 
sufficient data to conclude contrarily. Indeed, there is a dis-
tinct possibility that these lesions would have involuted re-
gardless of  exogenous estrogen status. Our cases, however, 
provide yet more anecdotal evidence to the body of  litera-
ture that suggests that exogenous estrogens may contribute 
to the growth or maintenance of  FNH lesions. Due to the 
amount of  conflicting data in the FNH literature, and the 
fact that many conclusions on the effect of  exogenous es-
trogens are founded on weakly significant data, further 
study is necessary to firmly establish the role of  OCPs in 
the natural history of  FNH. MRI is now an ideal modality 
for the diagnosis and followup of  FNH, as it has well-
defined diagnostic criteria for FNH and eliminates the car-
cinogenic ionizing radiation of  CT and operator depend-
ence of  ultrasound. Therefore, a case-control or prospective 
cohort study that employs long followup using strictly de-
fined MRI criteria could potentially provide resolution.
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